Table I.
Patient characteristics.
| MCH | NLR | ||||||
|---|---|---|---|---|---|---|---|
| Characteristics | Overall | Low | High | P-value | Low | High | P-value |
| Patients | 162 (100%) | 83 | 79 | 80 | 82 | ||
| Age ± SD (years) | 50.8±10.6 | 50.6±10.1 | 50.9±11.1 | 0.847 | 51.9±10.3 | 49.9±10.8 | 0.228 |
| T stage, n | 0.379 | 0.774 | |||||
| T1 | 53 | 26 | 27 | 28 | 25 | ||
| T2 | 89 | 50 | 39 | 44 | 45 | ||
| T3 | 17 | 6 | 11 | 6 | 9 | ||
| T4 | 3 | 1 | 2 | 2 | 1 | ||
| N stage, n (%) | 0.915 | 0.345 | |||||
| N0 | 73 (45.1) | 36 | 37 | 37 | 36 | ||
| N1 | 42 (25.9) | 23 | 19 | 23 | 19 | ||
| N2 | 22 (13.6) | 12 | 10 | 7 | 15 | ||
| N3 | 25 (15.4) | 12 | 13 | 13 | 12 | ||
| Histological grade, n (%) | 0.216 | 0.593 | |||||
| I/II | 120 (74.1) | 65 | 55 | 61 | 59 | ||
| III | 42 (25.9) | 18 | 24 | 19 | 23 | ||
| Clinical stage, n (%) | 0.616 | 0.241 | |||||
| I/II | 110 (67.9) | 58 | 52 | 58 | 52 | ||
| III | 52 (32.1) | 25 | 27 | 22 | 30 | ||
| ER, n (%) | 0.552 | 0.156 | |||||
| Positive | 87 (53.7) | 46 | 41 | 38 | 49 | ||
| Negative | 74 (45.7) | 37 | 37 | 42 | 32 | ||
| Unkonwn | 1 (0.6) | 0 | 1 | 0 | 1 | ||
| PR, n (%) | 0.888 | 0.156 | |||||
| Positive | 77 (47.6) | 41 | 36 | 32 | 45 | ||
| Negative | 83 (51.2) | 41 | 42 | 48 | 35 | ||
| Unkonwn | 2 (1.2) | 1 | 1 | 0 | 2 | ||
| Her2, n (%) | 0.044 | 0.1406 | |||||
| Positive | 37 (22.8) | 13 | 24 | 22 | 15 | ||
| Negative | 124 (76.5) | 70 | 54 | 58 | 76 | ||
| Unkonwn | 1 (0.6) | 0 | 1 | 0 | 1 | ||
MCH, mean corpuscular hemoglobin; NLR, neutrophil-to-lymphocyte ratio; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; SD, standard deviation.